Key result
Technetium-99m perfusion imaging agents can be successfully employed for the determination of myocardial viability in patients with severe regional dysfunction and chronic coronary artery disease.
Why the study?
Are technetium-99m-labeled myocardial perfusion agents adequate for the detection of myocardial viability compared to Thallium-201 in patients with ischemic cardiomyopathy?
Population
Patients with coronary artery disease and depressed left ventricular function (ischemic cardiomyopathy)
Comparison
Technetium-99m perfusion agents vs Thallium-201 (201Tl) imaging
Design
Review
Authors
Loading...
Supports technetium-99m viability imaging in chronic CAD; leaves open prospective trials versus thallium-201.
Are technetium-99m-labeled myocardial perfusion agents adequate for the detection of myocardial viability compared to Thallium-201 in patients with ischemic cardiomyopathy?
Technetium-99m-labeled agents are valid alternatives to Thallium-201 for assessing myocardial viability in patients with ischemic cardiomyopathy.
Caner et al. (1998) conducted a review in Coronary artery disease and depressed left ventricular function. Technetium-99m-labeled myocardial perfusion agents (99mTc-sestamibi and 99mTc-tetrofosmin) vs. Thallium-201 (201Tl) was evaluated on Detection of myocardial viability. Technetium-99m perfusion imaging agents can be successfully employed for the determination of myocardial viability in patients with severe regional dysfunction and chronic coronary artery disease.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: